Latest Articles and Analysis

On April 24, 2026, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a Dear Colleague letter that withdraws federal funding eligibility from fentanyl test strips, sterile...

The HIV/HCV Co-Infection Watch is a project of the Community Access National Network (CANN) designed to research, monitor, and report on HIV and Hepatitis C (HCV) co-infection in the United States....

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

340B program drifted from patient benefit; federal reform needed for transparency and accountability.

CANN marks 30th anniversary with expanded partnerships and cross-condition advocacy evolution.

Lupus Colorado partnership with CANN demonstrates how disease-specific and multi-condition advocates amplify healthcare policy impact.

2025 healthcare crises result from policy choices as ACA subsidies expire, HIV care deteriorates, and state pricing experiments proliferate.

Most Favored Nation pricing threatens to import restrictive QALY-based frameworks that discriminate against expensive treatments.

Expiration of enhanced ACA subsidies threatens to increase premiums 75% and reduce marketplace enrollment by millions.

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

RFK Jr's Administration for a Healthy America proposes to dismantle infectious disease capacity while emphasizing unproven chronic disease theories.

Healthcare policy equality forms the foundation for LGBTQ+ liberation and health equity in prevention and treatment access.

Caregiving infrastructure supports health equity and healthcare outcomes, requiring policy investment in caregiving infrastructure.

CMS draft guidance on 340B claims modifiers creates ambiguity and enforcement gaps threatening program integrity and beneficiary access.

RFK Jr's budget testimony reveals plans to restructure HHS agencies and shift funding away from infectious disease prevention.

Pharmacy benefit managers extract billions while adding no value, increasing costs without improving patient access or health outcomes.

Trump administration's contradictory drug pricing policies undermine goals of affordability and innovation incentives.

Elimination of health equity research funding undermines evidence base for addressing healthcare disparities and structural inequalities.

Pragmatic approach to healthcare policy reform requires accepting incremental progress while maintaining advocacy commitment.

Reflection on advocacy values and health equity commitment during political transitions.